Anna Suk‐Fong Lok

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

Ching‐Lung Lai, Anna Suk‐Fong Lok, Pui–Chee Wu et al. · Cancer · 1988 · 361 citations · Full text

Surgical Oncology, Adria Laboratories, Pathology +18

PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN

Ching‐Lung Lai, Hsiang‐Ju Lin, Eng‐Kiong Yeoh et al. · The Lancet · 1987 · 171 citations

Immunodeficiencies, Immunology, Antiviral Therapy +3

HEPATITIS B VIRUS INFECTION IN CHINESE FAMILIES IN HONGKONG

Anna Suk‐Fong Lok, Ching‐Lung Lai, Pui–Chee Wu et al. · American Journal of Epidemiology · 1987 · 136 citations

Vaccination, Maternal Immunization, Susceptible Family Members +14

Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference

Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault et al. · Hepatology · 2019 · 105 citations · Full text

Immunology, Hepatitis B, Hbv Functional Cure +18

Characterization of Genotype-Specific Carboxyl-Terminal Cleavage Sites of Hepatitis B Virus e Antigen Precursor and Identification of Furin as the Candidate Enzyme

Kiyoaki Ito, Kyun‐Hwan Kim, Anna Suk‐Fong Lok et al. · Journal of Virology · 2009 · 83 citations · Full text

Immunology, Hepatitis B, Molecular Biology +20